Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Food for thought... increased attention
View:
Post by Quentin30 on Dec 01, 2022 6:38pm

Food for thought... increased attention

Try running a Youtube search for Oncolytics Biotech... there are plenty of videos dating back to the dark ages of Brad Thomson, spewing all kinds of nonsense about seamless Phase III trials... pure BS in retrospect.

But those videos and Ellis Reports only have a few hundred views at best...

Roll on the latest interview with Matt a couple of weeks ago, and views are already numbering 3.7k... ten times those of previous years.

Hopefully this signals a shift of focus BACK to ONCY. Today's news was most welcome, but do remember that in one of those interviews from 2017, Matt is talking of having received Fast Track approval for mBC, and we know how long it's taken to get to running a Phase III from that... 

If history repeats, then tomorrow may start up, finish slightly down, and then continue dropping until after the poster presentations, only to drop back to where the run started. I hope I'm wrong this time, but long termers have seen this time and time again.

GLTA
Comment by Hydroqc on Dec 01, 2022 7:03pm
I think you have a buble air travelling between your ears. And we don't need a biomarker to find out.
Comment by Noteable on Dec 01, 2022 7:25pm
Noteable (1329)   November 28, 2022 - 02:16 PM Post# 35134482 RE:RE:RE:RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stock The poster Quentin is a product of the Yahoo message board ... where manipulative crticism has been its primary modus operandi.
Comment by Buckhenry on Dec 01, 2022 7:35pm
Quentin. I think it would be best for you to sell and get out. if you don't see the writing on the wall now its probably means you have drain bambage that is irreversibly. otherwise you could try your hand at shorting if you have the cahones for it and the funds to back up and cover your shorts...
Comment by Buckhenry on Dec 01, 2022 7:49pm
Fast Track designation is designed to facilitate the development and expedite the review of therapies to treat serious conditions and fill an unmet medical need. For conditions where an available treatment exists, a therapy must show some advantage over the available treatment, such as superior effectiveness, to be granted a Fast Track designation. A clinical program that receives Fast Track ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities